<DOC>
	<DOCNO>NCT00394914</DOCNO>
	<brief_summary>This randomize , multi-center , double-blind , placebo-controlled study evaluate efficacy pleconaril nasal spray prevent asthma exacerbation common cold symptom asthmatic participant expose picornavirus respiratory infection . Participants assign treatment pleconaril placebo nasal spray 7 day ( 14 dos ) . Participants follow additional 14 day .</brief_summary>
	<brief_title>Effects Pleconaril Nasal Spray Common Cold Symptoms Asthma Exacerbations Following Rhinovirus Exposure ( Study P04295 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Common Cold</mesh_term>
	<mesh_term>Picornaviridae Infections</mesh_term>
	<mesh_term>Pleconaril</mesh_term>
	<criteria>Must ≥6 ≤65 year age , either sex , race , diagnosis asthma least 2 year prior Screening Visit . Must history two upper respiratory infectioninduced asthma exacerbation past 24 month . For participant 6 17 year age , exacerbation purpose inclusion criterion , define : An increase four puff shortacting betaagonist ( SABA ) per day least 3 consecutive day , An increase two nebulizations SABA per day least 3 consecutive day , Documentation morning ( AM ) peak flow drop &gt; 20 % per day least 2 consecutive day , Documentation AM peak flow drop ≥50 % least 1 day . Must stable dose asthma medication ( include immunotherapy ) least 1 month prior Screening Visit . Must prebronchodilator FEV1 ≥50 % predict Screening Visit , prohibit medication withhold specify interval . If reversibility test perform within previous 24 month , participant , ≥17 year age , must demonstrate increase absolute FEV1 ≥12 % , absolute volume increase least 200 mL . A participant &lt; 17 year age , must demonstrate increase absolute FEV1 ≥12 % . Must cohabit least one person ( family member , roommate ) . A participant ( participant 's legal representation ) must willing give write informed consent able adhere dose visit schedule . Must free clinically significant disease , asthma , would interfere study evaluation . Must general good health , confirm routine clinical laboratory test . All laboratory test ( Complete Blood Count , blood chemistry , urinalysis ) elctrocardiograms must within normal limit clinically acceptable investigator/sponsor . Female childbearing potential must use medically acceptable , adequate form birth control . Had upper low respiratory illness exhibit sign and/or symptoms respiratory illness 4 week prior Screening Visit . Received treatment recently indicate washout period prior Screening must continue receive treatment prohibit . Smoker exsmoker smoke within previous 5 year Screening cumulative smoking history &gt; 10 pack year . Allergy/sensitivity study drug excipients . Female breastfeeding , pregnant , intend become pregnant . Used investigational drug within 30 day Screening . Participating clinical study . Part staff personnel directly involve study . Family member investigational study staff .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>